{"schema_version":"secwatch.filing_event.v1","accession":"0001566044-25-000007","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.769009+00:00","generated_at":"2026-05-16T23:41:12.455362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VYNE reports Q3 net loss $7.3M; cash $32.7M; strategic review ongoing","bullets":["Net loss $7.3M ($0.17 per share) vs $12.2M ($0.29) in Q3 2024; revenue $0.2M from Finacea royalty.","Cash, cash equivalents and marketable securities $32.7M as of Sep 30, 2025; runway into first half 2027.","FDA partial clinical hold on VYN202 for male subjects; 12-week dog tox study ongoing to resolve.","Phase 2b repibresib gel for vitiligo failed primary endpoint F-VASI50; trial being terminated.","Board initiated strategic review in Aug 2025; evaluating partnerships, M&A, asset sales; LifeSci Capital engaged."],"urls":{"canonical":"https://secwatch.observer/filing/0001566044-25-000007","json":"https://secwatch.observer/filing/0001566044-25-000007.json","markdown":"https://secwatch.observer/filing/0001566044-25-000007.md","text":"https://secwatch.observer/filing/0001566044-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000156604425000007/0001566044-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000156604425000007/mnlo-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:41:12.455362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}